Innoviva (INVA) 10-K2014 FY Annual report

Filed: 27 Feb 15, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: absent, absorb, acknowledged, aclidinium, add, aged, Aguiar, allegation, appointed, Arnuity, Assumption, AstaZeneca, Australian, avoid, bank, benchmark, beneficiary, Boehringer, broader, cautionary, comment, confidence, conflict, contemplation, default, differentiate, disagreement, disinterested, dispute, downsized, Duaklir, earliest, efficient, employed, encourage, Eric, fewer, fluctuate, formulary, frame, fumarate, Genuair, glycopryyonium, glycopyrronium, harbor, hereof, hypothetical, impede, inaccuracy, inaction, Incruse, Ingelheim, innovation, inquire, inquired, installment, instance, landlord, landscape, light, Medicare, merchandise, Michael, mixture, nearest, notable, older, Organizational, outsourcing, PBS, permanent, person, post, president, pressure, pro, promulgated, properly, rata, refinance, refinanced, repaid, repayment, representation, resold, resolution, resumed, retroactively, Rick, rounded, routine, routinely, Salford, Sanoz, satisfaction, Scheme, Seebri, segregated, sensitivity, shielded, shortfall, size, smaller, sNDA, spring, substance, suited, supersede, tranche, Tudorza, turn, unconsolidated, unpredictable, verbal, VIE, warranty, withdrawn, withheld, wrote

Removed: abroad, accelerate, acceleration, accident, analgesia, animal, antibacterial, antibiotic, ARNI, arranged, attachment, attack, attract, attractive, bacteria, bacterial, baseline, Bay, bill, biological, biologically, biology, bladder, body, bound, breadth, brought, CA, cancelable, cancelled, capability, cardiovascular, catastrophic, cease, ceased, ceftaroline, chemistry, civil, collaborate, collaborator, collateralized, compelling, complementary, computer, concentrate, concomitantly, conducting, confidential, confined, conserve, considerably, constipation, consulting, contact, contamination, convenience, conventional, counterpart, creating, creation, cSSSI, Cubicin, Cubist, currency, curtail, damage, daptomycin, declare, defective, defend, Defense, deficiency, demonstration, depending, designing, deterioration, devote, difficulty, dilution, disaster, disorder, dissuade, distribute, disturbance, earn, earthquake, educate, electrical, eliminate, emerge, enhance, enhanced, enrolling, ensuring, entering, environmental, Equivalence, eroding, establish, eventual, eventually, exceeded, excipient, executory, exhibit, expansion, expertise, expiratory, exploiting, exposed, extend, extremist, fatal, fault, FDAApproved, fire, forced, Forest, forgo, formulation, FP, fulfill, gastrointestinal, gene, Gilead, granting, grow, handling, heavily, heterodimer, idiopathic, importing, Improve, improving, inadvertent, incomplete, inexpensive, inhibitor, injury, insight, instituting, institution, insufficient, integration, internally, internationally, interrupted, introduction, investigating, investigation, involuntary, involved, Janssen, joined, joining, largely, leading, lend, leverage, leveraging, linezolid, linking, liquidation, listed, locate, manufactured, MARIN, meaningful, misappropriation, molecule, monovalency, motility, mu, multivalency, multivalent, narrow, natural, negotiate, network, norepinephrine, nosocomial, notified, opioid, opposed, optimization, oral, Orange, overactive, overcome, pain, pandemic, partnering, penalized, people, Peripheral, peripherally, Pfizer, Pharmaceutica, pipeline, placebo, pneumonia, political, potency, potent, practice, preference, promotional, propionate, protecting, protocol, quickly, radioactive, ranging, reach, real, receptor, recover, recruit, recruiting, reflecting, relinquish, relinquished, renew, renewal, rental, reproduce, returned, reuptake, revise, ruled, scaled, scheduled, Science, scientific, secure, selective, selectively, selectivity, sequence, serotonin, showing, simultaneously, site, skin, Squibb, stage, stemming, stopped, storage, strategically, stronger, strongly, struck, structural, structurally, sued, sufficiency, superior, supplier, suspected, Teflaro, telavancin, telecommunication, terminable, terrorism, terrorist, therapeutic, threatened, tigecycline, tolerability, tolerated, topline, Tygacil, uncured, unique, unproven, unrealizable, unreleased, unreliable, unrest, unsuccessful, vancomycin, variability, volume, voluntary, vulnerable, war, waste, wide, workforce, Zyvox

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

INVA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32

CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER
AND CHIEF FINANCIAL OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Michael W. Aguiar, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report of Theravance, Inc. on Form 10-K for the fiscal year ended December 31, 2014 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended and that information contained in such Annual Report on Form 10-K fairly presents in all material respects the financial condition of Theravance, Inc. at the end of the periods covered by such Annual Report on Form 10-K and results of operations of Theravance, Inc. for the periods covered by such Annual Report on Form 10-K.


Date: February 27, 2015		By:		/s/ Michael W. Aguiar Michael W. Aguiar Chief Executive Officer

I, Eric d'Esparbes, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report of Theravance, Inc. on Form 10-K for the fiscal year ended December 31, 2014 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended and that information contained in such Annual Report on Form 10-K fairly presents in all material respects the financial condition of Theravance, Inc. at the end of the periods covered by such Annual Report on Form 10-K and results of operations of Theravance, Inc. for the periods covered by such Annual Report on Form 10-K.


Date: February 27, 2015		By:		/s/ Eric d'Esparbes Eric d'Esparbes Senior Vice President and Chief Financial Officer

A signed original of this written statement required by Section 906 has been provided to Theravance, Inc. and will be retained by it and furnished to the Securities and Exchange Commission or its staff upon request.